


**Greater expansion fold with higher Naïve and Central memory T cell population**



Ave (n = 6)	2% AB serum	2% UG-P GI	2% plasma
<b>Expansion</b>	998 folds	<b>2336 folds</b>	1527 folds
<b>T cell %</b>	80	85	78
<b>Naïve T %</b>	4.8	<b>7.4</b>	2.5
<b>CM T %</b>	14.4	<b>27.8</b>	8.6

Fig 2. PBMCs were collected from 6 healthy donors, and T cells were activated by applying a commercial kit from supplier B, followed by the manufacturer's protocol to compare the induction performance with AB serum, UG-P GI, and auto-plasma. The results showed greater T cells with higher population of Naïve and central memory T cells could be obtained by introducing UG-P GI.



**Greater Naïve T and central memory T cells were induced**

**Favorable for CAR-T cell production and immunotherapy**

### Ordering Information

Product Number	Product	Bottle Size (mL)
HPCHXCGLI05	UltraGRO™ -PURE GI GMP	50
HPCHXCGLI10		100
HPCHXCGLI150		500



Distributed by  
**CliniSciences Group**

## *Xeno-free and Viral Inactivated for Therapeutic T cell Activation*



AventaCell BioMedical has adopted a state-of-the-art gamma irradiation process, as our pathogen reduction treatment (PRT), for viral inactivation to create the UltraGRO™-PURE GI (“UG-P GI”) product. The xeno-free fibrinogen-depleted human platelet lysate, **UG-P GI** offers minimized pathogen contamination risk while preserving potent cell culture performance with human immune cells and other applicable cell types for clinical applications.

### Benefits of UltraGRO™-PURE GI

- **US FDA FMD# 34284**
- **JAPAN PMDA Certificate**
- **Ph. Eur. General Chapter 5.2.12.4 Compliance**
- Xeno-free serum substitute
- Abundant natural growth factors and proteins
- Gamma irradiation PRT accepted by all major regulatory agencies
- GI safeguard of 99.99%+ viral clearance
- Viral inactivated products w/o loss of potency
- Ideal for producing clinical grade immune cells



### *Greater expansion fold with higher Naïve and Central memory T cell population*



Ave (n = 5)	1% AB serum	1% UG-P GI	1% plasma
Expansion	1321 folds	<b>2610 folds</b>	1708 folds
T cell %	86	82	83
Naïve T %	6.0	<b>9.6</b>	2.5
CM T %	5.0	<b>15.5</b>	6

Fig 1. PBMCs were collected from 5 healthy donors, and T cells were activated by applying a commercial kit from supplier A, followed by the manufacturer’s protocol to compare the induction performance with AB serum, UG-P GI, and auto-plasma. The results showed greater T cells with higher population of Naïve and central memory T cells could be obtained by introducing UG-P GI.

Distributed by  
**CliniSciences Group**



# CliniSciences

## Austria

Company: CliniSciences GmbH  
Address: Sternwartestrasse 76, A-1180  
Wien - Austria  
Telephone: +43 720 115 580  
Fax: +43 720 115 577  
Email: [oesterreich@clinisciences.com](mailto:oesterreich@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Belgium

Company: CliniSciences S.R.L  
Address: Avenue Stalingrad 52, 1000  
Brussels - Belgium  
Telephone: +32 2 31 50 800  
Fax: +32 2 31 50 801  
Email: [belgium@clinisciences.com](mailto:belgium@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Denmark

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [denmark@clinisciences.com](mailto:denmark@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Finland

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [suomi@clinisciences.com](mailto:suomi@clinisciences.com)  
Web: <https://www.clinisciences.com>



## France

Company: CliniSciences S.A.S  
Address: 74 Rue des Suisses, 92000  
Nanterre- France  
Telephone: +33 9 77 40 09 09  
Fax: +33 9 77 40 10 11  
Email: [info@clinisciences.com](mailto:info@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Germany

Company: Biotrend Chemikalien GmbH  
Address: Wilhelm-Mausier-Str. 41-43,  
50827 Köln - Germany  
Telephone: +49 221 9498 320  
Fax: +49 221 9498 325  
Email: [info@biotrend.com](mailto:info@biotrend.com)  
Web: <https://www.biotrend.com>



## Iceland

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [island@clinisciences.com](mailto:island@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Ireland

Company: CliniSciences Limited  
Address: Ground Floor, 71 lower Baggot street  
Dublin D02 P593 - Ireland  
Telephone: +353 1 6971 146  
Fax: +353 1 6971 147  
Email: [ireland@clinisciences.com](mailto:ireland@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Italy

Company: CliniSciences S.r.l  
Address: Via Maremmana inferiore 378  
Roma 00012 Guidonia Montecelio - Italy  
Telephone: +39 06 94 80 56 71  
Fax: +39 06 94 80 00 21  
Email: [italia@clinisciences.com](mailto:italia@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Netherlands

Company: CliniSciences B.V.  
Address: Gaetano Martinolaan 85, 6229  
GS Maastricht - Netherlands  
Telephone: +31 85 2082 351  
Fax: +31 85 2082 353  
Email: [nederland@clinisciences.com](mailto:nederland@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Norway

Company: CliniSciences AS  
Address: c/o MerVerdi Munkerudtunet 10  
1164 Oslo - Norway  
Telephone: +47 21 988 882  
Email: [norge@clinisciences.com](mailto:norge@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Poland

Company: CliniSciences sp.Z.o.o.  
Address: ul. Rotmistrza Witolda Pileckiego 67  
lok. 200 - 02-781 Warszawa -Poland  
Telephone: +48 22 307 0535  
Fax: +48 22 307 0532  
Email: [polska@clinisciences.com](mailto:polska@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Portugal

Company: Quimigen Unipessoal LDA  
Address: Rua Almada Negreiros, Lote 5, Loja 14,  
2615-275 Alverca Do Ribatejo - Portugal  
Telephone: +351 30 8808 050  
Fax: +351 30 8808 052  
Email: [info@quimigen.com](mailto:info@quimigen.com)  
Web: <https://www.quimigen.pt>



## Spain

Company: CliniSciences Lab Solutions  
Address: C/ Hermanos del Moral 13  
(Bajo E), 28019, Madrid - Spain  
Telephone: +34 91 269 40 65  
Fax: +34 91 269 40 74  
Email: [espana@clinisciences.com](mailto:espana@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Sweden

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [sverige@clinisciences.com](mailto:sverige@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Switzerland

Company: CliniSciences AG  
Address: Fracht Ost Flughafen Kloten  
CH-8058 Zürich - Switzerland  
Telephone: +41 (044) 805 76 81  
Fax: +41 (044) 805 76 75  
Email: [switzerland@clinisciences.com](mailto:switzerland@clinisciences.com)  
Web: <https://www.clinisciences.com>



## UK

Company: CliniSciences Limited  
Address: 11 Progress Business center, Whittle  
Parkway, SL1 6DQ Slough- United Kingdom  
Telephone: +44 (0)1753 866 511  
or +44 (0) 330 684 0982  
Fax: +44 (0)1753 208 899  
Email: [uk@clinisciences.com](mailto:uk@clinisciences.com)  
Web: <https://www.clinisciences.com>



## USA

Company: Biotrend Chemicals LLC  
Address: c/o Carr Riggs Ingram,  
500 Grand Boulevard, Suite 210 Miramar  
Beach, FL 32550- USA  
Telephone: +1 850 650 7790  
Fax: +1 850 650 4383  
Email: [info@biotrend-usa.com](mailto:info@biotrend-usa.com)  
Web: <https://www.biotrend-usa.com>

